Femilis LNG IUS | The Contraceptive Pipeline Database

Product Overview

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Intrauterine

Duration Type: Long-acting

Description: IUS releasing ~20mcg of levonorgestrel daily, expected to last for at least 5 years. In vitro study suggest constant rate of LNG release similar to the Mirena. Four products with the Femilis name have been developed. They are various sizes, contain different amounts of levonorgestrel, and have different durations of use.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): levonorgestrel

Potential Multi-Purpose Technology (MPT): No

Duration: 5 years

Dose: 20 mcg

Partner: Contrel Research, Belgium, APCOR R&M, Belgium

Status

Project Phase: Post-development

Project Stage: Regulatory

Programmatic Considerations

Considerations:
Shorter cross-arm simplifies insertion technique and could promote use by non specialist providers.

Additional Information

Additional Information:
Wildemeersch D, et al. (2005) Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 71(6):465-9.

Wildemeersch D, et al. (2016) Femilis® 60 Levonorgestrel-Releasing Intrauterine System—A Review of 10 Years of Clinical Experience. Clin Med Insights Reprod Health. 2016; 10: 19–27.

Wildemeersch D, et al. (2017) Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecol Endocrinol. 2017 Mar;33(3):223-226.

Download Product Report